Professor Bart Meuris at the University Hospitals in Leuven, Belgium conducted the cardiac heart valve surgery.
Fifteen patients will be enrolled in the first-in-human study and followed up for 6 months after receiving implantation of the ADAPT valve.
Results from the study are expected between first quarter of 2021 and third quarter of 2021.
Data will provide “insights to the valve function”
Chief executive officer Wayne Paterson said: “This is a huge milestone for Admedus.
“The data collected on these patients will give us insights to the valve function in the near term proving highly valuable to our TAVR program.
“The preliminary post-operative data initially collected were highly encouraging.
“The trial’s objective is to demonstrate implantation safely.
“It will also provide useful insights into the tissue science and valve design.
“This will help us confirm the clinical benefits relating to haemodynamic function and durability, [while] further building on our strong body of data we have.”
Coronavirus mitigation strategy
Admedus recently confirmed that it will implement a Coronavirus mitigation strategy to limit the risk of an interruption to the continuity of supply and operations.
The company expects the impacts on operations to be minimal but will monitor the situation closely.
In the meantime, the company continues operating to plan and key projects are progressing as scheduled.